文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

不适合移植的新诊断多发性骨髓瘤患者的治疗方案：系统文献回顾和网络荟萃分析。

Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

机构信息

Department of Haematology, Lille University Hospital, Lille, France.

Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain.

出版信息

Adv Ther. 2022 May;39(5):1976-1992. doi: 10.1007/s12325-022-02083-8. Epub 2022 Mar 5.

DOI:10.1007/s12325-022-02083-8
PMID:35246820
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9056460/
Abstract

INTRODUCTION: Many treatment regimens have been evaluated in transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). The objective of this study was to compare the efficacy of relevant therapies for the treatment of TIE patients with NDMM. METHODS: Progression-free survival (PFS) and overall survival (OS) from large randomised controlled trials (RCTs) evaluating different treatment options for TIE patients with NDMM were compared in a network meta-analysis (NMA). The NMA includes recent primary and long-term OS readouts from SWOG S0777, ENDURANCE, MAIA, and ALCYONE. Relevant trials were identified through a systematic literature review. Relative efficacy measures (i.e., hazard ratios [HRs] for PFS and OS) were extracted and synthesised in random-effects NMAs. RESULTS: A total of 122 publications describing 45 unique RCTs was identified. Continuous lenalidomide/dexamethasone (Rd) was selected as the referent comparator. Daratumumab-containing treatments (daratumumab/lenalidomide/dexamethasone [D-Rd], daratumumab/bortezomib/melphalan/prednisone [D-VMP]) and bortezomib/lenalidomide/dexamethasone (VRd) had the highest probabilities of being more effective than Rd continuous for PFS (HR: D-Rd, 0.53; D-VMP, 0.57, VRd, 0.77) and OS (HR: D-Rd, 0.68; VRd, 0.77, D-VMP, 0.78). D-Rd had the highest chance of being ranked as the most effective treatment with respect to PFS and OS. Results using a smaller network focusing on only those regimens that are relevant in Europe were consistent with the primary analysis. CONCLUSIONS: These comparative effectiveness data may help inform treatment selection in TIE patients with NDMM.

摘要

简介：许多治疗方案已在不适合移植（TIE）的新发多发性骨髓瘤（NDMM）患者中进行了评估。本研究的目的是比较治疗 TIE 患者 NDMM 的相关治疗的疗效。

方法：通过网络荟萃分析（NMA）比较评估 TIE 患者 NDMM 不同治疗方案的大型随机对照试验（RCT）的无进展生存期（PFS）和总生存期（OS）。NMA 包括 SWOG S0777、ENDURANCE、MAIA 和 ALCYONE 的最新主要和长期 OS 结果。通过系统文献回顾确定相关试验。提取并以随机效应 NMA 综合相对疗效指标（即 PFS 和 OS 的风险比 [HR]）。

结果：共确定了 122 篇描述 45 项独特 RCT 的出版物。连续来那度胺/地塞米松（Rd）被选为参考对照。含达雷妥尤单抗的治疗方案（达雷妥尤单抗/来那度胺/地塞米松[D-Rd]、达雷妥尤单抗/硼替佐米/马法兰/泼尼松[D-VMP]）和硼替佐米/来那度胺/地塞米松（VRd）与 Rd 连续治疗相比，PFS（HR：D-Rd，0.53；D-VMP，0.57，VRd，0.77）和 OS（HR：D-Rd，0.68；VRd，0.77，D-VMP，0.78）的有效性更高的可能性最大。D-Rd 最有可能被评为最有效的治疗方案，在 PFS 和 OS 方面。仅关注在欧洲相关的方案的较小网络的分析结果与主要分析一致。

结论：这些比较有效性数据可能有助于为 TIE 患者 NDMM 的治疗选择提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/c4a506381197/12325_2022_2083_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/b2acae2459d6/12325_2022_2083_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/1ba5e134b8b5/12325_2022_2083_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/d3875872f7c6/12325_2022_2083_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/c703f251fff9/12325_2022_2083_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/0ad0a974f00d/12325_2022_2083_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/c4a506381197/12325_2022_2083_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/b2acae2459d6/12325_2022_2083_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/1ba5e134b8b5/12325_2022_2083_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/d3875872f7c6/12325_2022_2083_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/c703f251fff9/12325_2022_2083_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/0ad0a974f00d/12325_2022_2083_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ae/9056460/c4a506381197/12325_2022_2083_Fig6_HTML.jpg

相似文献

[1]
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

Adv Ther. 2022-5

[2]
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.

Adv Ther. 2024-5

[3]
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Health Technol Assess. 2011-12

[4]
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.

Cochrane Database Syst Rev. 2019-11-25

[5]
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

Cochrane Database Syst Rev. 2021-5-4

[6]
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Cochrane Database Syst Rev. 2020-10-19

[7]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[8]
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.

Leuk Lymphoma. 2017-1

[9]
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.

Lancet Haematol. 2025-2

[10]
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Health Technol Assess. 2007-11

引用本文的文献

[1]
Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis.

Hematol Oncol. 2025-5

[2]
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review.

Cancer Med. 2025-3

[3]
Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study.

BMC Cancer. 2025-2-28

[4]
Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Cancer Med. 2024-11

[5]
Improving Health Outcomes Through Treatment Sequencing Optimization in Multiple Myeloma: A Simulation Model in Transplant-Ineligible Patients.

Cancer Rep (Hoboken). 2024-10

[6]
Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.

Clin Exp Med. 2024-8-6

[7]
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel.

Future Oncol. 2024

[8]
Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor.

Front Immunol. 2024

[9]
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.

Front Pharmacol. 2024-5-9

[10]
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.

Adv Ther. 2024-5

本文引用的文献

[1]
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

Hemasphere. 2021-2-3

[2]
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2020-12-2

[3]
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Lancet Oncol. 2020-8-28

[4]
Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.

J Geriatr Oncol. 2020-11

[5]
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).

Blood Cancer J. 2020-5-11

[6]
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.

Am J Hematol. 2020-4-23

[7]
Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients.

Eur J Haematol. 2020-7

[8]
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Lancet. 2019-12-10

[9]
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.

Cochrane Database Syst Rev. 2019-11-25

[10]
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.

Leuk Lymphoma. 2020-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索